Nitarsone-Mediated CREB Preservation via Jacob-LMO4 Disruption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments are inadequate for preventing amyloid-β-induced transcriptional inactivation of CREB, which leads to synaptic dysfunction and neurodegeneration in diseases like Alzheimer's disease and ALS.
Innovation Solution
The use of the compound nitarsone or its derivatives to inhibit Jacob-induced inactivation of CREB by disrupting the molecular interaction between Jacob and LMO4, thereby preserving CREB's transcriptional activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If amyloid-β oligomers are present in the brain, then synaptic function deteriorates and neurodegeneration occurs, but no effective treatment currently exists to prevent this progression
Solution Approach 1:
The patent introduces Jacob as an intermediary protein that mediates the harmful effect of amyloid-β on CREB. Amyloid-β does not directly inactivate CREB but rather activates Jacob, which then translocates to the nucleus and displaces LMO4 from CREB, causing indirect CREB inactivation. This intermediary mechanism allows for targeted intervention.
Solution Approach 2:
The patent extracts the harmful function by separating and removing Jacob from the CREB complex. By displacing LMO4 from CREB using Jacob as a tool, the system achieves CREB inactivation. The therapeutic strategy then involves blocking Jacob's ability to displace LMO4, effectively removing the harmful intermediary action while preserving beneficial CREB activity.
2Reliability
If CREB is inactivated by Jacob, then transcriptional activity is lost leading to synaptic dysfunction, but blocking Jacob prevents this protective mechanism
Solution Approach 1:
The patent applies local quality by differentiating between the nuclear and cytoplasmic functions of Jacob. In the cytoplasm, Jacob serves a beneficial role in signal transduction. In the nucleus, it causes harmful CREB inactivation. The therapeutic intervention specifically blocks Jacob's nuclear translocation or its ability to displace LMO4, thereby preventing the harmful local effect while preserving the beneficial cytoplasmic function.
3Reliability
If LMO4 is displaced from CREB by Jacob, then CREB becomes transcriptionally inactive, but LMO4 is a crucial transcriptional co-activator
Solution Approach 1:
LMO4 serves as a critical intermediary co-activator between CREB and target genes. Jacob's displacement of LMO4 from CREB is the key mechanism that shuts down transcriptional activity. The therapeutic strategy focuses on preventing this displacement, thereby maintaining LMO4's role as a transcriptional co-activator and preserving CREB's ability to regulate gene expression.
Data Source
AI summary
A compound nitarsone, or salt thereof is provided for use in the treatment of a neurodegenerative disease, such as Alzheimer's disease (AD), dementia, Parkinson's disease (RD) or amyotrophic lateral sclerosis (ALS). A pharmaceutical composition is also provided that includes compound, or salt thereof for use in the treatment of a neurodegenerative disease.